PT Kalbe Farma Tbk LCLA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- IDR 0.08
- Day Range
- IDR 0.08–0.08
- 52-Week Range
- IDR 0.02–—
- Bid/Ask
- IDR 0.00 / IDR 0.00
- Market Cap
- IDR 3.52 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 20.48
- Price/Sales
- 1.90
- Dividend Yield (Trailing)
- 2.33%
- Dividend Yield (Forward)
- 2.33%
- Total Yield
- 2.33%
Company Profile
PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. Majority of the company's gross profits are derived from the distribution and logistics segments. The company operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 13,062
- Website
- https://www.kalbe.co.id
Comparables
Valuation
|
Metric
|
LCLA
|
EPMT
|
TSPC
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.48 | 8.93 | 8.77 |
Price/Book Value | 2.70 | 0.82 | 1.10 |
Price/Sales | 1.90 | 0.21 | 0.67 |
Price/Cash Flow | 15.35 | 9.50 | 5.90 |
Price/Earnings
LCLA
EPMT
TSPC
Financial Strength
|
Metric
|
LCLA
|
EPMT
|
TSPC
|
|---|---|---|---|
Quick Ratio | 2.45 | 1.27 | 2.01 |
Current Ratio | 4.31 | 2.32 | 2.75 |
Interest Coverage | 48.50 | 59.65 | 17.76 |
Quick Ratio
LCLA
EPMT
TSPC
Profitability
|
Metric
|
LCLA
|
EPMT
|
TSPC
|
|---|---|---|---|
Return on Assets (Normalized) | 10.44% | 6.28% | 9.85% |
Return on Equity (Normalized) | 13.70% | 9.68% | 14.61% |
Return on Invested Capital (Normalized) | 12.05% | 9.52% | 11.54% |
Return on Assets
LCLA
EPMT
TSPC
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Rhgqrfrbc | Ddrmq | $834.9 Bil | |||
| Johnson & Johnson
JNJ
| Rqvlhdln | Sfyn | $350.3 Bil | |||
| Merck & Co Inc
MRK
| Ylfcrjw | Bzqf | $327.9 Bil | |||
| AbbVie Inc
ABBV
| Thxjxfll | Wqj | $297.7 Bil | |||
| AstraZeneca PLC ADR
AZN
| Mkbqjcfwbn | Sjxpf | $247.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Znvmjtdk | Dkgs | $223.9 Bil | |||
| Novartis AG ADR
NVS
| Jrkjtznc | Mpw | $216.8 Bil | |||
| Amgen Inc
AMGN
| Hpxsffkhkw | Vqym | $160.2 Bil | |||
| Pfizer Inc
PFE
| Mttfkspy | Bdt | $156.0 Bil | |||
| Sanofi SA ADR
SNY
| Yfhysfrq | Vygp | $116.1 Bil |